<bill session="117" type="h" number="8641" updated="2022-12-29T19:03:42Z">
  <state datetime="2022-08-02">REFERRED</state>
  <status>
    <introduced datetime="2022-08-02"/>
  </status>
  <introduced datetime="2022-08-02"/>
  <titles>
    <title type="display">Orphan Drug COVID&#226;&#8364;&#8220;19 Mitigation Act of 2022</title>
    <title type="short" as="introduced">Orphan Drug COVID&#226;&#8364;&#8220;19 Mitigation Act of 2022</title>
    <title type="official" as="introduced">To mitigate the effects of the COVID-19 pandemic on incentives under the Federal Food, Drug, and Cosmetic for the development of orphan drugs, and for other purposes.</title>
  </titles>
  <sponsor bioguide_id="G000583"/>
  <cosponsors>
    <cosponsor bioguide_id="B001298" joined="2022-08-02"/>
    <cosponsor bioguide_id="D000631" joined="2022-08-02"/>
    <cosponsor bioguide_id="S001180" joined="2022-10-21"/>
  </cosponsors>
  <actions>
    <action datetime="2022-08-02">
      <text>Introduced in House</text>
    </action>
    <action datetime="2022-08-02" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
  </subjects>
  <amendments/>
  <summary date="2022-12-21T15:59:41Z" status="Introduced in House">Orphan Drug COVID-19 Mitigation Act of 2022

This bill extends by 180 days the relevant periods of market exclusivity for drugs for rare diseases or conditions (i.e., orphan drugs) for which applications were submitted during the COVID-19 emergency period.</summary>
</bill>
